Lanton Law

Lanton Law Blog

Learn about the latest trends and activities through our blog posts.

Posts tagged Food and Drug Administration
Cancer Moonshot Initiative Returns
Cancer Moonshot Initiative Returns

In 2017 we wrote an article that previewed the Cancer Moonshot Initiative (CMI). It was a widespread belief that with Joe Biden becoming President that the CMI would return in some capacity. Today, the White House issued a Fact Sheet that has reginited this policy effort.

Read More
Biosimilars, biologics, CMS, healthcare, HHS, oncology, pharmaceuticalsRon LantonCancer Moonshot Initiative, President Joe Biden, oncology, Health and Human Services, National Cancer Institute, Food and Drug Administration, Centers for Medicare & Medicaid Services
FDA Approves First Interchangeable Biosimilar for Humira
FDA Approves First Interchangeable Biosimilar for Humira

According to the FDA’s press release, “The U.S. Food and Drug Administration approved the first interchangeable biosimilar product to treat certain inflammatory diseases.”

Read More
Biosimilars, biotech, biologics, FDA, insurance, life sciences, healthcare, pharmaceuticals, pharmacy, pharmacy benefit managerRon LantonInterchangeable Biosimilar, biosimilars, Cyltezo, Boehringer Ingelheim, FDA, Food and Drug Administration